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Abstract
Background: Levels of the cardiac muscle regulatory protein troponin T (cTnT) are frequently elevated in patients with
acute ischemic stroke and elevated cTnT predicts poor outcome and mortality. The pathomechanism of troponin
release may relate to co-morbid coronary artery disease and myocardial ischemia or, alternatively, to neurogenic cardiac
damage due to autonomic activation after acute ischemic stroke. Therefore, there is uncertainty about how acute
ischemic stroke patients with increased cTnT levels should be managed regarding diagnostic and therapeutic workup.
Methods/Design: The primary objective of the prospective observational trial TRELAS (TRoponin ELevation in
Acute ischemic Stroke) is to investigate the frequency and underlying pathomechanism of cTnT elevation in acute
ischemic stroke patients in order to give guidance for clinical practice. All consecutive patients with acute ischemic
stroke admitted within 72 hours after symptom onset to the Department of Neurology at the Campus Benjamin
Franklin of the University Hospital Charité will be screened for cTnT elevations (i.e. >= 0.05 μg/l) on admission and
again on the following day. Patients with increased cTnT will undergo coronary angiography within 72 hours.
Diagnostic findings of coronary angiograms will be compared with age- and gender-matched patients presenting
with Non-ST-Elevation myocardial infarction to the Department of Cardiology. The primary endpoint of the study
will be the occurrence of culprit lesions in the coronary angiogram indicating underlying co-morbid obstructive
coronary artery disease. Secondary endpoints will be the localization of stroke in the cerebral imaging and left
ventriculographic findings of wall motion abnormalities suggestive of stroke-induced global cardiac dysfunction.
Discussion: TRELAS will prospectively determine the frequency and possible etiology of troponin elevation in a
large cohort of ischemic stroke patients. The findings are expected to contribute to clarify pathophysiologic
concepts of co-morbid cardiac damage in ischemic stroke patients and also to provide a basis for clinical
recommendations for cardiac workup of such patients.
Trial registration: clinicaltrials.gov NCT01263964
Background
F i g h t i n gh e a r td i s e a s ea n ds t r o k ei st h ea g e n d ao ft h e
American Heart Association. What is more, the two dis-
eases show intense connections as indicated by the high
proportion of strokes with cardioembolic origin. More-
over, cardiac derangement has been observed in the con-
text of acute neurological disorders causing myocardial
dysfunction, arrhythmia, ECG alterations and rise of
cardiac troponins [1,2].
The troponin protein complex consists of three subu-
nits, namely troponin C, I and T, and contributes to
the modulation of striated muscle contraction. Cardiac
troponin C is identical to its skeletal isoform, but for tro-
ponin I and troponin T unique cardiac isoforms were
identified. Monoclonal antibodies distinguish cardiac tro-
ponin T (cTnT) isoforms from fetal cardiac and skeletal
isoforms without cross-reactivity, allowing the conclusion
that elevation of cTnT in the blood stream always reflects
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myocardial injury is not revealed in the individual case,
because increased cTnT was also found in the absence of
thrombotic occlusion of a coronary vessel in other clini-
cal conditions with cardiac injury or strain, such as heart
failure, perimyocarditis, supraventricular tachycardias
and pulmonary embolism [5,6]. Moreover, approximately
50% of the patients with renal insufficiency show
increased cTnT values in the absence of symptoms of
myocardial infarction [7]. This may relate to associated
left ventricular (LV) hypertrophy, “silent” micro-infarc-
tions or decreased renal troponin excretion [5,7].
Interestingly, increased cTnT was also reported to
occur in 5-34% of patients with acute ischemic stroke
[8]. In several studies, the elevation of cTnT was asso-
ciated with stroke severity on hospital admission, insular
cortex lesions, short- and long-term clinical outcome
and increased risk of mortality [9-12], indicating prog-
nostic significance of increased cTnT in acute ischemic
stroke.
In the individual stroke patient the cause of troponin
elevation is uncertain. One possible explanation in some
patients may be the coincidence of acute coronary syn-
drome (ACS) leading to ischemic myocardial necrosis.
This notion is supported by the fact that stroke and
myocardial infarction share common risk factors and by
the high prevalence of coronary artery disease (CAD) in
stroke patients [13].
Neurogenic cardiac damage is another possible cause.
Cardiac injury might result from autonomic imbalance
after stroke affecting cortical areas controlling autonomic
function, e.g. the insular cortex. A subsequent catechola-
mine surge may induce global LV dysfunction with ven-
triculographic findings of LV apical ballooning [14,15].
Due to the uncertainty regarding the underlying etiology
of cTnT elevation in ischemic stroke patients the extent
and time point of cardiologic work-up in this clinical
situation is still under debate. Therefore, the aim of TRE-
LAS is to determine the prevalence of troponin elevation
in a prospective cohort of ischemic stroke patients and to
display the frequency of underlying acute obstructive
CAD, as defined by angiographic culprit lesions. Further
objective is to clarify the frequency of associated neurocar-
diogenic LV dysfunction and insular cortex lesions.
Methods/Design
Study design and study population
TRELAS is a prospective observational, single centre,
matched-pair controlled trial conducted by the Center
for Stroke Research Berlin and the Department of Car-
diology at the Campus Benjamin Franklin of the Charité
University Hospital, Berlin. Patients with acute ischemic
s t r o k ea n de l e v a t e dc T n T ,m e e t i n gt h ei n c l u s i o na n d
exclusion criteria, as depicted in table 1, are eligible for
the study. Approval by the local ethics committee (EA4/
118/10) was obtained before trial registration in Decem-
ber 2010 (clinicaltrials.gov NCT01263964).
Procedures
All consecutive patients with imaging-confirmed ischemic
stroke admitted within 72 hours after symptom onset to
the Department of Neurology will be screened for
increased cTnT immediately on admission and the follow-
ing day. In the case of cTnT elevation (i.e. >= 0.05 μg/l)
and normal serum creatinine (<= 1.2 mg/dl) coronary
angiography (CAG) will be carried out within the next
72 hours. In the absence of culprit lesions, which are
defined as complex coronary stenoses as suggested by
Ambrose [16,17], further treatment will not include dual
antiaggregation. If a culprit lesion is present in the coron-
ary angiogram, coincident myocardial infarction is
regarded to be the cause of cTnT increase. Further inter-
vention will depend on individual risk-benefit analysis.
Possible complications of CAG during the study were dis-
cussed with the local ethics committee and will be docu-
mented accurately. Subsequent to CAG patients’ vital
signs, physical status, urinary excretion and peripheral
pulse status will be monitored by experienced physicians.
Monitoring will be done in the 12-bed Stroke Unit or on
the cardiologic Intensive Care Unit, respectively.
Age- and gender-matched patients with Non-ST-ele-
vation-ACS (NSTE-ACS), thus showing elevated tropo-
nin levels above 0.05 μg/l per definitionem,w i l ls e r v ea s
controls to allow comparison with regard to frequency
of culprit lesions and left ventricular (LV) dysfunction.
All patients admitted to the Department of Cardiology,
Campus Benjamin Franklin with NSTE-ACS who
undergo early CAG within 72 hours and who give
informed consent for participation will be eligible as
control group.
A flow chart of study procedures is depicted in Figure 1.
Diagnostic procedures and interpretation are described in
more detail in the respective section further below.
Table 1 TRELAS: Inclusion and exclusion criteria
Inclusion criteria
1. Acute ischemic stroke, confirmed by cerebral imaging
2. Inclusion within ≤ 72 hours after symptom onset
3. hsTroponin T ≥0.05 μg/l
Exclusion criteria
1. Impaired renal function (creatinine >1,2 mg/dl)
2. Limited life expectancy or premorbid mRS ≥ 4
3. Contraindications for coronary angiography
4. Age < 18 years
5. Pregnancy
6. Patient unwilling to give informed consent
7. ST- elevation myocardial infarction
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After recording of patient characteristics (age, gender,
stroke risk factors including arterial hypertension,
hypercholesterolemia, heart failure and atrial fibrillation,
history of coronary artery disease, chest pain according
to the Braunwald Classification [18], nicotine and alcohol
consumption and known malignant tumors) neurological
examination will be carried out by certified investigators
using the National Institute of Health Stroke Scale
(NIHSS) and modified Rankin scale (mRS). The NIHSS is
a validated tool used in many clinical trials to evaluate
stroke severity and graduate neurological deficits as well
as alterations during the patients’ hospital stay [19,20].
The mRS is a validated instrument to measure the degree
of disability [21,22]. Patients will be scored on admission
and on day 7 or on hospital discharge, which is typically
between day 4 and day 10 after hospital admission,
respectively. Data on demographic information, course of
symptoms and stroke etiology, classified by the TOAST
classification [23], will be recorded according to the
German Stroke database registry guidelines.
Laboratory measures
Serum cTnT levels are determined on admission using a
h i g hs e n s i t i v eT r o p o n i nTa s s a y( R o c h eE l e c s y s
® Tropo-
nin Ths, Mannheim, Germany) with an upper reference
limit for the 99
th percentile of the normal reference
population at 0.014 μg/l and a coefficient of variation of
less than 10% at 0.013 μg/l [24]. Our laboratory defined a
cut-off value of 0.05 μg/l to establish the diagnosis of
NSTE-ACS. This value is regarded to be equivalent to
0.03 μg/l, the cut-off value of fourth generation cTnT
assays [25]. If cTnT is below the cut-off on admission a
second blood sample will be obtained on the following
day. Further blood markers, including creatinine, are
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Figure 1 Flow chart of study procedures. Gray ellipses: Outcome measures, Green boxes: Study population, Red boxes: Excluded population;
Abbreviations: ICU: Intensive Care Unit, mRS: modified Rankin Scale, NSTE-ACS: Non-ST-elevation acute coronary syndrome, SU: Stroke Unit.
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admission and in the course of the hospital stay.
Coronary angiography and further cardiologic work-up
CAG will be performed by trained cardiologists accord-
ing to local guidelines. The respective CAG procedure
itself as well as the usage of specific devices will be left to
experience and expert knowledge of the cardiologist. To
determine coronary status both coronary arteries will be
visualized. Complex coronary stenoses showing irregular
borders, ulceration or filling defects suggestive of the pre-
sence of intracoronary thrombus will be defined as cul-
prit lesions as suggested by Ambrose [17]. Furthermore,
left ventriculography will be performed to record wall
motion abnormalities, especially LV apical ballooning
[26]. Patients will be informed about procedure-related
risks a second time independently by the cardiologist
performing the examination. All patients will undergo
routine diagnostic work-up including standard 12-lead
ECG, Holter-ECG and transesophageal ultrasound
according to recommendations of the German Stroke
Society [27].
Cerebral imaging
Brain imaging will be performed according to ongoing
institutional protocols. Whenever possible imaging will be
done by using 3T MRI (Tim Trio, Siemens AG, Erlangen,
Germany) [28]. Otherwise, cerebral computed tomography
(64-slice, Siemens AG, Erlangen, Germany) will be used.
Stroke localization will be determined by experienced neu-
roradiologists blinded to clinical details. Findings will be
dichotomized into absence or presence of insular cortex
involvement. Furthermore, the affected brain circulation
territory will be specified as right anterior, left anterior or
posterior circulation.
Hypotheses and outcomes
The primary hypothesis of TRELAS is that cTnT eleva-
tion in acute stroke patients is generally not caused by
coincidental myocardial infarction. Thus, we expect
angiographic culprit lesions to occur less frequently in
patients with acute stroke and elevated cTnT than in
patients with NSTE-ACS.
Furthermore, we hypothesize that strokes affecting the
insular cortex can be found more often in patients with
increased cTnT than with normal cTnT. A further sec-
ondary hypothesis is that LV global cardiac dysfunction
occurs more frequently in stroke patients with increased
cTnT than in patients with NSTE-ACS. Therefore, the
findings of the left ventriculography will serve as an out-
come measure.
Power calculation and sample size estimates
A power calculation was conducted based on literature
review describing the frequency of culprit lesions in 85%
of the patients with NSTE-ACS [29] and an estimated
occurrence of culprit lesions in 35% of stroke patients
with troponin elevation. We aim to include 58 patients,
29 patients with acute ischemic stroke and 29 age- and
gender-matched patients with NSTE-ACS, to detect the
estimated difference of 50% regarding the occurrence of
angiographic culprit lesions within the matched-pairs
with a statistical power of 90% at a significant level of
5%. This analysis included an estimated patient drop-
out rate of 20%.
Discussion
Elevated troponin levels are assumed to occur in up to 1
out of 6 patients presenting with acute cerebral ischemia
and are associated with stroke severity, unfavorable short-
and long-term clinical outcome [2,8]. Two candidate
mechanisms are regarded to be relevant for troponin ele-
vation in acute ischemic stroke when renal insufficiency is
excluded. First, coincident ACS may lead to focal ischemic
myocardial necrosis by means of thrombotic occlusion of
a coronary vessel. Second, stroke-induced autonomic
imbalance with subsequent surge of catecholamines could
induce global damage and dysfunction of myocardial tis-
sue and the release of cTnT. However, the underlying
cause of cTnT elevation in the individual stroke patient
remains questionable, leading to a diagnostic and thera-
peutic dilemma for the attending physician. In order to
rule out coincident ACS reliably coronary status has to be
clarified. However, estimated risks of cerebral bleeding
complications limit the diagnostic work-up using CAG in
patients with acute stroke.
Previous studies investigating troponin elevations in
patients with ischemic stroke mainly described the preva-
lence and prognostic significance but data concerning co-
existing acute CAD are scarce. Myocardial perfusion scin-
tigraphy was carried out by Jensen et al. in 11 acute stroke
patients with elevated cTnT, a cohort too small to produce
significant results [11]. So far, no study has used CAG to
determine coronary status in patients with elevated cTnT
and acute cerebral ischemia.
All stroke patients included in TRELAS will undergo
CAG in order to determine the frequency of coronary cul-
prit lesions associated to cTnT elevation. CAG is regarded
to be the diagnostic gold standard for establishing the
diagnosis of myocardial infarction [30,31]. Although non-
invasive coronary CT imaging substantially improved over
the last years, current guidelines recommend CAG in a
clinical situation suggestive of myocardial infarction [30].
Moreover, using CAG enables therapeutic intervention if a
culprit lesion was identified. Within our study CAG will
be done within 72 hours as recommended by guidelines of
the American Heart Association and European Society of
Cardiology for patients with NSTE-ACS and high likeli-
hood of CAD [30,31] because patients with NSTE-ACS
seem to benefit from early CAG [32]. We have not defined
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of all myocardial infarctions in the elderly remain clinically
“silent” [33,34]. In fact, cardiovascular disease is the most
common cause of death in one-year stroke survivors [35]
and a substantial amount of stroke patients have asympto-
matic coronary stenoses [13] indicating CAD.
A reason for not performing CAG in stroke patients are
safety concerns with an increased risk of brain hemorrhagic
transformation and parenchymal hemorrhage because of
anticoagulation during the procedure. However, only small
amounts of heparin, if any, need to be administered during
CAG and the increased risk of bleeding is rather caused by
double-antiaggregation following application of coronary
stents. In a recent study, CAG was performed in order to
show previously unknown CAD in a large cohort of
patients with ischemic stroke and proved to be safe even in
the early phase of acute stroke (6-11 days after onset). In
315 stroke patients undergoing CAG no procedural
adverse event was observed except one groin hematoma
[13].
A further objective of the TRELAS study is to investigate
whether there is a correlation between troponin elevation
and ischemia in the insular cortex which is regarded to
play a crucial role in controlling the autonomic nervous
system [36]. In particular, right-sided insular lesions have
been linked to disturbance of autonomic balance [37].
Interestingly, Ay et al. conducted a voxel-wise analysis of
diffusion weighted imaging lesions and reported a signifi-
cant association of right insular cortex involvement and
cTnT elevation [12]. However, Barber et al. found no asso-
ciation of insular cortex stroke and increased serum cTnT
[38]. We hope the results of TRELAS to contribute to this
issue.
Another aim of TRELAS is to assess the relation
between neurogenic cardiac dysfunction and troponin ele-
vation in ischemic stroke patients. Several studies reported
disturbance of autonomic cardiac function with LV wall
motion abnormalities in patients with acute ischemic
stroke or subarachnoidal hemorrhage, respectively
[14,39,40]. In this context a unique kind of cardiomyopa-
thy, termed Takotsubo cardiomyopathy (TTC), seems
noteworthy. Excessive catecholamine levels in the context
of acute stressful events cause LV dysfunction with LV
apical ballooning in TTC [41], frequently combined with
cTnT elevation despite of missing CAD [26]. Diagnosis of
TTC can be established via CAG and left ventriculography
because the cardiac wall motion abnormalities associated
with TTC can usually be shown and concomitant obstruc-
tive CAD can be ruled out simultaneously [26]. The results
of TRELAS will contribute to the question whether cTnT
elevation in ischemic stroke is associated with myocardial
LV dysfunction, and whether TTC is a relevant differential
diagnosis in this clinical situation.
Impaired renal function is an exclusion criteria
because diagnostic sensitivity to detect ACS is decreased
in patients with renal failure [42] and those patients are
prone to adverse effects of the contrast agents adminis-
tered for CAG. Nevertheless, only a few studies with
troponin elevation in stroke excluded patients with renal
insufficiency [12,15,43].
To properly detect elevations of cTnT a high-sensitive
troponin assay will be used. The assay was established
recently to improve diagnostic precision, which is neces-
sary according to the 2007 consensus definition of acute
myocardial infarction [44]. We do not expect significant
inclusion of “false positive” patients in TRELAS because
of the chosen cut-off, which is equal to cut-offs of for-
mer fourth cTnT assays [25] and the exclusion of
patients with impaired renal function.
There are some limitations of our study. First of all,
CAG is conducted in a rather small cohort of 29 stroke
patients. This sample size is adjusted to show a 50% dif-
ference in the occurrence of coronary culprit lesions
between the matched-pairs. Thus, smaller differences
are not detectable with a respective statistical power.
Second, power estimation was carried out for finding
significant results concerning the primary endpoint.
Therefore, it might not be possible to present significant
findings concerning the secondary endpoints. Third, the
cerebral imaging modality will probably be heteroge-
neous in our study sample due to impossibility to ensure
MRI in each stroke patient.
Taken together, troponin elevation is a frequent obser-
vation in patients with acute ischemic stroke and is
associated with adverse outcome. As the underlying
mechanism in the individual case is unclear there is a con-
siderable diagnostic and therapeutic uncertainty. A focal
cardiac ischemia due to acute rupture of coronary plaques
requires urgent initiation of invasive cardiac diagnostics
and intensified therapy. However, a proven stroke-
mediated cardiomyopathy would open doors for heart
protection strategies. The observational TRELAS trial will
describe the prevalence of troponin elevation in a prospec-
t i v ec o h o r to fa c u t ei s c h e m i cs t r o k ep a t i e n t sa n dw i l l
determine the frequency of possible etiological causes.
Our findings may provide a basis for further recommenda-
tions regarding the extent and time point of cardiac work-
up in this clinical setting.
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